CN117142989A - Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same - Google Patents

Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same Download PDF

Info

Publication number
CN117142989A
CN117142989A CN202311034040.3A CN202311034040A CN117142989A CN 117142989 A CN117142989 A CN 117142989A CN 202311034040 A CN202311034040 A CN 202311034040A CN 117142989 A CN117142989 A CN 117142989A
Authority
CN
China
Prior art keywords
crystal
hiv drug
formula
drug intermediate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311034040.3A
Other languages
Chinese (zh)
Inventor
匡善明
孔敏敏
张心旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Feiteng Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Feiteng Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Feiteng Pharmaceutical Technology Co ltd filed Critical Shanghai Feiteng Pharmaceutical Technology Co ltd
Priority to CN202311034040.3A priority Critical patent/CN117142989A/en
Publication of CN117142989A publication Critical patent/CN117142989A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The application relates to a growth method of an anti-HIV drug intermediate crystal, the obtained crystal and application thereof, wherein the growth method comprises the following steps: dissolving the raw materials in methanol at 55-65deg.C, filtering, cooling the filtrate to 20-30deg.C at a speed of 0.05-0.15deg.C/min, and separating to obtain crystals; the raw materials are crude anti-HIV drug intermediates; the structure of the anti-HIV drug intermediate is shown as a formula I. The growth method of the anti-HIV drug intermediate crystal is simple and easy to operate, and the prepared compound crystal shown in the formula A is a rod-shaped solid in appearance, thereby being beneficial to the purification operation; the crystal is stable, which is beneficial to reducing impurities generated in the storage process when the next reaction is carried out, and improving the yield and quality of synthesis; in the reaction of further preparing the anti-HIV medicine, the crystal can also obviously improve the reaction rate.

Description

Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same
The application relates to a method for growing an anti-HIV drug intermediate crystal and a obtained crystal and application thereof, which are respectively filed by application number CN202011613178.5 and application date 2020, 12 months and 30 days.
Technical Field
The application belongs to the technical field of biological medicines, and particularly relates to a growth method of an anti-HIV drug intermediate crystal and the obtained crystal.
Background
The tert-butyl (2S, 3R) -3-hydroxy-4- (N-isobutyl-4-nitrobenzenesulfonamino) -1-phenylbutane-2-carbamate can be used for preparing anti-HIV medicines such as fosamprenavir calcium, darunavir, amprenavir and the like, and is an important intermediate. The results are shown below:
wherein, the synthetic route of the fosamprenavir calcium is as follows:
wherein, the synthesis route of the amprenavir is shown as follows:
the synthesis route of the darunavir is as follows:
as a key intermediate for preparing various APIs, the stability of the crystalline form of tert-butyl (2 s,3 r) -3-hydroxy-4- (N-isobutyl-4-nitrobenzenesulfonamino) -1-phenylbutane-2-carbamate is advantageous in reducing impurities generated during the next reaction and improving the yield and quality of the synthesis.
Patent WO2006131757 discloses that tert-butyl (2 s,3 r) -3-hydroxy-4- (N-isobutyl-4-nitrobenzenesulfonamino) -1-phenylbutane-2-carbamate needs to be separated, transferred and stored before further reaction, but the crystal form of the product is fibrous in appearance, difficult to filter, easy to leave solvent, difficult to transfer and difficult to handle.
The preparation method of tert-butyl (2S, 3R) -3-hydroxy-4- (N-isobutyl-4-nitrobenzenesulfonamino) -1-phenylbutane-2-carbamate disclosed in patent WO2006131757 is to heat a saturated solution and cool the saturated solution to obtain crystals, or to crystallize the crystals in the cooling process. The stability of the final crystal form is poor.
Disclosure of Invention
Aiming at the defects of the prior art, the application aims to provide a growth method of an anti-HIV drug intermediate crystal, the obtained crystal and application thereof.
In order to achieve the aim of the application, the application adopts the following technical scheme:
in a first aspect, the application provides a method for growing an anti-HIV drug intermediate crystal, which is characterized by comprising the following steps:
dissolving the raw materials in methanol at 55-65deg.C, filtering, cooling the filtrate to 20-30deg.C at a speed of 0.05-0.15 deg.C/min, stirring for 2-3 hr, and separating to obtain crystals;
the raw materials are crude anti-HIV drug intermediates;
the structure of the anti-HIV drug intermediate is shown as a formula I:
the growth method of the anti-HIV drug intermediate crystal is simple and easy to operate, and the prepared compound crystal shown in the formula I is a rod-shaped solid in appearance, thereby being beneficial to the purification operation; the crystal is stable, which is beneficial to reducing impurities generated in the storage process when the next reaction is carried out, and improving the yield and quality of synthesis; in the reaction of further preparing the anti-HIV medicine, the crystal can also obviously improve the reaction rate.
The 55-65deg.C may be 55 deg.C, 56 deg.C, 57 deg.C, 58 deg.C, 59 deg.C, 60 deg.C, 61 deg.C, 62 deg.C, 63 deg.C, 64 deg.C or 65 deg.C, etc., and other specific values within this range may be selected, and will not be described here again.
The above 0.05-0.15 ℃/min may be, for example, 0.05 ℃/min, 0.06 ℃/min, 0.07 ℃/min, 0.08 ℃/min, 0.09 ℃/min, 0.10 ℃/min, 0.11 ℃/min, 0.12 ℃/min, 0.13 ℃/min, 0.14 ℃/min or 0.15 ℃/min, and other specific values within the range may be selected, and will not be described in detail herein.
The cooling rate is specifically selected to be 0.05-0.15 deg.c/min because crystallization of the fiber morphology occurs if the rate is further increased.
The above 20-30deg.C may be, for example, 20deg.C, 21deg.C, 22deg.C, 23deg.C, 25deg.C, 26deg.C, 27deg.C, 28deg.C, 29 deg.C or 30deg.C, etc., and other specific values within this range may be selected, and will not be described here again.
Preferably, the mass volume ratio of the raw materials to the methanol is as follows: each 500mg of the raw material is dissolved in 4-12mL (e.g., 4mL, 5mL, 5.5mL, 6mL, 6.5mL, 7mL, 8mL, 9mL, 10mL, 11mL, 12mL, etc.), and other specific values within this range are selectable, and will not be described in detail herein). Preferably, the mass volume ratio of the raw materials to the methanol is as follows: each 500mg of the starting material was dissolved in 4-8mL of methanol. Preferably, the mass volume ratio of the raw materials to the methanol is as follows: each 500mg of the starting material was dissolved in 5.5-6.5mL of methanol.
Preferably, the cooling rate is 0.09-0.11 ℃/min.
Preferably, the filtrate is cooled to 24-26 ℃.
Preferably, the dissolution of the starting material in methanol is carried out at 58-62 ℃.
In a second aspect, the present application provides a compound crystal a of formula I prepared by the growth method of an anti-HIV drug intermediate crystal, where the X-ray diffraction pattern of the compound crystal a of formula I has characteristic diffraction peaks at 8.38±0.2°, 9.44±0.2°, 13.80±0.2°, 16.56±0.2°, 18.82±0.2°, 19.08±0.2°, 19.62±0.2°, and 23.58±0.2°.
The crystal is a rod-shaped solid in appearance, which is helpful for the purification operation; the crystal is stable, which is beneficial to reducing impurities generated in the process of storage in the next reaction and improving the yield and quality of synthesis.
In a third aspect, the present application provides a method for preparing an anti-HIV drug intermediate crystal, the method comprising: heating the compound crystal A shown in the formula I to 100-170deg.C (such as 100deg.C, 110deg.C, 115 deg.C, 120 deg.C, 125 deg.C, 130 deg.C, 140 deg.C, 160 deg.C, 170 deg.C, etc.), preferably 115-125deg.C, to obtain compound crystal B shown in the formula I.
The heating temperature is specifically selected to be 100-170 c because the target compound of a specific crystal form cannot be produced if the temperature is further increased or decreased.
In a fourth aspect, the present application provides a compound crystal B of formula I, which is prepared by the preparation method described above, wherein the compound crystal B of formula I has characteristic diffraction peaks at 7.09±0.2°, 9.55±0.2°, 10.56±0.2°, 11.48±0.2°, 14.08±0.2°, 16.12±0.2°, 17.61±0.2° in an X-ray diffraction pattern.
The crystal is a rod-shaped solid in appearance, which is helpful for the purification operation; the crystal is stable, which is beneficial to reducing impurities generated in the process of storage in the next reaction and improving the yield and quality of synthesis.
In a fifth aspect, the present application also provides a preparation method of twelve anti-HIV drug intermediate crystals, where the preparation method is as follows: suspending the compound crystal B shown in the formula I in a solvent, wherein the solvent is respectively a first solvent, o-xylene, 2-butanol, N-butanol, acetic acid, 1, 2-dichloroethane, formamide, ethanol, formic acid, 1, 4-dioxypyrimidine, dimethyl sulfoxide and pyridine, standing for 48-96 hours at 20-30 ℃, and separating to obtain a compound crystal C, a crystal D, a crystal E, a crystal F, a crystal G, a crystal H, a crystal I, a crystal J, a crystal K, a crystal L, a crystal M and a crystal N shown in the formula I; the first solvent is any one of n-heptane, toluene or methylene dichloride.
The 48-96h may be, for example, 48h, 55h, 60h, 65h, 70h, 75h, 80h, 85h, 90h or 96h, etc., and other specific values in the range may be selected, which will not be described in detail herein.
Preferably, the suspension is performed at 20-40 ℃, for example, 20 ℃, 21 ℃, 22 ℃, 23 ℃, 24 ℃,25 ℃, 26 ℃, 27 ℃, 28 ℃, 29 ℃, 30 ℃, 35 ℃, 40 ℃ and the like, and other specific values within the range can be selected, and will not be described in detail herein.
Preferably, the dissolution is carried out at 24-26 ℃.
Preferably, the rest is carried out at 24-26 ℃ for 65-75 hours.
Preferably, the mass-volume ratio of the crystal B to the solvent is: each 50mg of crystal B is dissolved in 0.5-1.5mL (e.g., 0.5mL, 0.6mL, 0.7mL, 0.8mL, 0.9mL, 1.0mL, 1.1mL, 1.2mL, 1.3mL, 1.4mL, 1.5mL, etc.) of the solvent.
Preferably, the mass-volume ratio of the crystal B to the solvent is: each 500mg of crystal B is dissolved in 0.5-1.5mL (e.g., 0.5mL, 0.6mL, 0.7mL, 0.8mL, 0.9mL, 1.0mL, 1.1mL, 1.2mL, 1.3mL, 1.4mL, 1.5mL, etc.) of the solvent.
Twelve different crystal forms of the compound crystal shown in the formula I can be obtained by the preparation method, and the specific steps are as follows:
in a sixth aspect, the present application provides a compound crystal C of formula I having characteristic diffraction peaks at 6.96±0.2°, 9.98±0.2°, 10.40±0.2°, 11.04±0.2°, 13.92±0.2°, 16.41±0.2°, 17.97±0.2°, 21.11±0.2° in an X-ray diffraction pattern of the compound crystal C of formula I produced by the production method according to the fifth aspect.
In a seventh aspect, the present application provides a compound crystal D of formula I produced by the production method according to the fifth aspect, wherein the compound crystal D of formula I has characteristic diffraction peaks at 8.68±0.2°, 9.89±0.2°, 15.61±0.2°, 16.07±0.2°, 18.08±0.2°, 20.82±0.2°, 21.69±0.2°, 26.55±0.2° in an X-ray diffraction pattern.
In an eighth aspect, the present application provides a compound crystal E of formula I having characteristic diffraction peaks at 7.30±0.2°, 7.57±0.2°, 8.51±0.2°, 14.56±0.2°, 16.50±0.2°, 18.38±0.2°, 18.75±0.2°, 21.24±0.2° in an X-ray diffraction pattern of the compound crystal E prepared by the preparation method according to the fifth aspect.
In a ninth aspect, the present application provides a compound crystal F of formula I produced by the production method according to the fifth aspect, wherein the compound crystal F of formula I has characteristic diffraction peaks at 7.32±0.2°, 7.68±0.2°, 8.56±0.2°, 14.64±0.2°, 15.78±0.2°, 16.56±0.2°, 18.94±0.2°, 21.36±0.2° in an X-ray diffraction pattern.
In a tenth aspect, the present application provides a compound crystal G of formula I having characteristic diffraction peaks at 7.96±0.2°, 8.68±0.2°, 10.53±0.2°, 14.30±0.2°, 15.26±0.2°, 16.61±0.2°, 17.40±0.2°, 21.70 ±0.2° in an X-ray diffraction pattern of the compound crystal G prepared by the preparation method according to the fifth aspect.
In an eleventh aspect, the present application provides a compound crystal H of formula I having characteristic diffraction peaks at 6.38±0.2°, 8.76±0.2°, 9.71±0.2°, 15.93±0.2°, 17.13±0.2°, 18.89±0.2°, 19.96±0.2°, 22.17±0.2° in an X-ray diffraction pattern of the compound crystal H prepared by the preparation method according to the fifth aspect.
In a twelfth aspect, the present application provides a compound crystal I of formula I produced by the production method according to the fifth aspect, wherein the compound crystal I of formula I has characteristic diffraction peaks at 6.95±0.2°, 8.45±0.2°, 9.56±0.2°, 10.44±0.2°, 13.95±0.2°, 15.20±0.2°, 17.00±0.2°, 17.47±0.2° in an X-ray diffraction pattern.
In a thirteenth aspect, the present application provides a compound crystal J of formula I having characteristic diffraction peaks at 7.29±0.2°, 7.55±0.2°, 7.76±0.2°, 8.57±0.2°, 14.64±0.2°, 15.77±0.2°, 16.59±0.2°, 19.01 ±0.2° in an X-ray diffraction pattern of the compound crystal J produced by the production method according to the fifth aspect.
In a fourteenth aspect, the present application provides a compound crystal K of formula I having characteristic diffraction peaks at 7.52±0.2°, 8.26±0.2°, 9.36±0.2°, 15.16±0.2°, 16.64±0.2°, 19.23±0.2°, 19.76±0.2°, 23.46±0.2° in an X-ray diffraction pattern of the compound crystal K prepared by the preparation method according to the fifth aspect according to claim 6.
In a fifteenth aspect, the present application provides a compound crystal L of formula I having characteristic diffraction peaks at 6.39±0.2°, 9.53±0.2°, 10.00±0.2°, 15.86±0.2°, 16.51±0.2°, 18.29±0.2°, 19.30±0.2°, 21.24±0.2° in an X-ray diffraction pattern of the compound crystal L prepared by the preparation method according to the fifth aspect.
In a sixteenth aspect, the present application provides a compound crystal M of formula I having characteristic diffraction peaks at 6.27±0.2°, 10.68±0.2°, 12.32±0.2°, 14.99±0.2°, 18.47±0.2°, 20.34±0.2°, 25.44±0.2°, 26.26 ±0.2° in an X-ray diffraction pattern of the compound crystal M prepared by the preparation method according to the fifth aspect.
In a seventeenth aspect, the present application provides a compound crystal N of formula I having characteristic diffraction peaks at 7.56±0.2°, 8.78±0.2°, 10.68±0.2°, 12.66±0.2°, 14.46±0.2°, 15.98±0.2°, 17.77 ±0.2°, 18.52±0.2° in an X-ray diffraction pattern of the compound crystal N prepared by the preparation method according to the fifth aspect.
Compared with the prior art, the application has the following beneficial effects:
the growth method of the anti-HIV drug intermediate crystal is simple and easy to operate, and the prepared compound crystal shown in the formula I is a rod-shaped solid in appearance, thereby being beneficial to the purification operation; the crystal is stable, which is beneficial to reducing impurities generated in the storage process when the next reaction is carried out, and improving the yield and quality of synthesis; in the reaction of further preparing the anti-HIV medicine, the crystal can also obviously improve the reaction rate. The intermediate crystal of the anti-HIV medicine can be used as a raw material to further prepare other thirteen novel intermediate crystals of the compound shown in the formula I, and the crystals also have similar beneficial effects.
Drawings
FIG. 1 is an XRPD pattern for the crystals produced in example 1;
FIG. 2 is a DSC profile of the crystal prepared in example 1;
FIG. 3 is an XRPD pattern for the crystals produced in example 2;
FIG. 4 is a DSC characterization of the crystals produced in example 2;
FIG. 5 is an XRPD pattern for the crystals produced in example 3;
FIG. 6 is a DSC characterization of the crystals produced in example 3;
FIG. 7 is an XRPD pattern for the crystals produced in example 4;
FIG. 8 is a DSC profile of the crystal prepared in example 4;
FIG. 9 is an XRPD pattern for the crystals produced in example 5;
FIG. 10 is a DSC characterization of the crystals produced in example 5;
FIG. 11 is an XRPD pattern for the crystals produced in example 6;
FIG. 12 is a DSC characterization of the crystals produced in example 6;
FIG. 13 is an XRPD pattern for the crystals produced in example 7;
FIG. 14 is a DSC characterization of the crystal prepared in example 7;
FIG. 15 is an XRPD pattern for the crystals produced in example 8;
FIG. 16 is a DSC characterization of the crystal prepared in example 8;
FIG. 17 is an XRPD pattern for the crystals produced in example 9;
FIG. 18 is a DSC characterization of the crystal prepared in example 9;
FIG. 19 is an XRPD pattern for the crystals produced in example 10;
FIG. 20 is a DSC characterization of the crystals produced in example 10;
FIG. 21 is an XRPD pattern for the crystals produced in example 11;
FIG. 22 is a DSC chart of the crystal prepared in example 11;
FIG. 23 is an XRPD pattern for the crystals produced in example 12;
FIG. 24 is a DSC characterization of the crystals produced in example 12;
FIG. 25 is an XRPD pattern for the crystals produced in example 13;
FIG. 26 is a DSC characterization of the crystal prepared in example 13;
FIG. 27 is an XRPD pattern for the crystals produced in example 14;
FIG. 28 is a DSC characterization of the resulting crystal of example 14;
FIG. 29 is a representation of XRPD patterns before and after stability testing of form B;
FIG. 30 is a representation of XRPD patterns before and after stability testing of form C;
FIG. 31 is a DVS plot of form A;
FIG. 32 is a representation of XRPD patterns before and after a form A hygroscopicity test;
FIG. 33 is a DVS plot of form B;
fig. 34 is an XRPD characterization of form B before and after the hygroscopicity test.
Detailed Description
The technical scheme of the application is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the application and are not to be construed as a specific limitation thereof.
The compounds involved in the crystals in the following examples are all compounds as shown in formula I:
the raw materials involved in the following examples are all self-made, and the self-made method is referred to patent WO2008132154.
Example 1
This example provides a crystal of a compound of formula I, prepared as follows:
500mg of the starting material was dissolved in 6mL of methanol at 60℃and filtered. The filtered solution was then cooled to 25℃at a rate of 0.1℃per minute and isolated to give crystals.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 8.38.+ -. 0.2 °, 9.44.+ -. 0.2 °, 13.80.+ -. 0.2 °, 16.56.+ -. 0.2 °, 18.82.+ -. 0.2 °, 19.08.+ -. 0.2 °, 19.62.+ -. 0.2 °, 23.58.+ -. 0.2 °, as shown in fig. 1. Further characterized by DSC, which has two endothermic peaks at-90℃and-174℃respectively, as shown in FIG. 2.
Example 2
This example provides a crystal of a compound of formula I, prepared as follows:
10mg of the crystals of example 1 were placed in a DSC pan and heated to 120℃using DSC.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.09.+ -. 0.2 °, 9.55.+ -. 0.2 °, 10.56.+ -. 0.2 °, 11.48.+ -. 0.2 °, 14.08.+ -. 0.2 °, 16.12.+ -. 0.2 °, 17.61.+ -. 0.2 °, as shown in fig. 3. Further characterized by DSC, it has an endothermic peak at-174℃as shown in FIG. 4.
Example 3-1
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of n-heptane to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.96.+ -. 0.2 °, 9.98.+ -. 0.2 °, 10.40.+ -. 0.2 °, 11.04.+ -. 0.2 °, 13.92.+ -. 0.2 °, 16.41.+ -. 0.2 °, 17.97.+ -. 0.2 °, 21.11.+ -. 0.2 °, as shown in fig. 5. Further characterized by DSC, it has an endothermic peak at 173 ℃, as shown in figure 6.
Example 3-2
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of toluene to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.96.+ -. 0.2 °, 9.98.+ -. 0.2 °, 10.40.+ -. 0.2 °, 11.04.+ -. 0.2 °, 13.92.+ -. 0.2 °, 16.41.+ -. 0.2 °, 17.97.+ -. 0.2 °, 21.11.+ -. 0.2 ° as in example 3-1.
Examples 3 to 3
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of methylene chloride to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.96.+ -. 0.2 °, 9.98.+ -. 0.2 °, 10.40.+ -. 0.2 °, 11.04.+ -. 0.2 °, 13.92.+ -. 0.2 °, 16.41.+ -. 0.2 °, 17.97.+ -. 0.2 °, 21.11.+ -. 0.2 ° as in example 3-1.
Example 4
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of o-xylene to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 8.68.+ -. 0.2 °, 9.89.+ -. 0.2 °, 15.61.+ -. 0.2 °, 16.07.+ -. 0.2 °, 18.08.+ -. 0.2 °, 20.82.+ -. 0.2 °, 21.69.+ -. 0.2 °, 26.55.+ -. 0.2 °, as shown in fig. 7. Further characterized by DSC, it has three endothermic peaks at 109 ℃, 114 ℃ and 173 ℃, as shown in FIG. 8.
Example 5
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of 2-butanol to form a suspension, which was magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.30.+ -. 0.2 °, 7.57.+ -. 0.2 °, 8.51.+ -. 0.2 °, 14.56.+ -. 0.2 °, 16.50.+ -. 0.2 °, 18.38.+ -. 0.2 °, 18.75.+ -. 0.2 °, 21.24.+ -. 0.2 °, as shown in fig. 9. Further characterized by DSC, it has two endothermic peaks at 104℃and 173℃as shown in FIG. 10.
Example 6
This example provides a crystal of a compound of formula I, prepared as follows:
50mg of the crystals of example 2 were suspended in 1mL of n-butanol to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.32.+ -. 0.2 °, 7.68.+ -. 0.2 °, 8.56.+ -. 0.2 °, 14.64.+ -. 0.2 °, 15.78.+ -. 0.2 °, 16.56.+ -. 0.2 °, 18.94.+ -. 0.2 °, 21.36.+ -. 0.2 °, as shown in fig. 11. Further characterized by DSC, it has three endothermic peaks at 69 ℃, 100 ℃ and 173 ℃, as shown in FIG. 12.
Example 7
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of acetic acid to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.96.+ -. 0.2 °, 8.68.+ -. 0.2 °, 10.53.+ -. 0.2 °, 14.30.+ -. 0.2 °, 15.26.+ -. 0.2 °, 16.61.+ -. 0.2 °, 17.40.+ -. 0.2 °, 21.70.+ -. 0.2 °, as shown in fig. 13. Further characterized by DSC, it has three endothermic peaks at 109 ℃, 164 ℃ and 170 ℃, as shown in FIG. 14.
Example 8
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of 1, 2-dichloroethane to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.38.+ -. 0.2 °, 8.76.+ -. 0.2 °, 9.71.+ -. 0.2 °, 15.93.+ -. 0.2 °, 17.13.+ -. 0.2 °, 18.89.+ -. 0.2 °, 19.96.+ -. 0.2 °, 22.17.+ -. 0.2 °, as shown in fig. 15. Further characterized by DSC, it has two endothermic peaks at 123℃and 173℃as shown in FIG. 16.
Example 9
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of formamide to form a suspension, which was magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.95.+ -. 0.2 °, 8.45.+ -. 0.2 °, 9.56.+ -. 0.2 °, 10.44.+ -. 0.2 °, 13.95.+ -. 0.2 °, 15.20.+ -. 0.2 °, 17.00.+ -. 0.2 °, 17.47.+ -. 0.2 °, as shown in FIG. 17. Further characterized by DSC, it has three endothermic peaks at 103 ℃, 137 ℃ and 191 ℃, as shown in FIG. 18.
Example 10
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of ethanol to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.29.+ -. 0.2 °, 7.55.+ -. 0.2 °, 7.76.+ -. 0.2 °, 8.57.+ -. 0.2 °, 14.64.+ -. 0.2 °, 15.77.+ -. 0.2 °, 16.59.+ -. 0.2 °, 19.01.+ -. 0.2 °, as shown in fig. 19. Further characterized by DSC, it has three endothermic peaks at 75 ℃, 106 ℃ and 173 ℃, as shown in FIG. 20.
Example 11
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of formic acid to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.52.+ -. 0.2 °, 8.26.+ -. 0.2 °, 9.36.+ -. 0.2 °, 15.16.+ -. 0.2 °, 16.64.+ -. 0.2 °, 19.23.+ -. 0.2 °, 19.76.+ -. 0.2 °, 23.46.+ -. 0.2 °, as shown in fig. 21. Further characterized by DSC, it has four endothermic peaks at 88 ℃, 118 ℃, 136 ℃ and 148 ℃ as shown in FIG. 22.
Example 12
This example provides a crystal of a compound of formula I, prepared as follows:
100mg of the crystals of example 2 were suspended in 1mL of 1, 4-dioxapyrimidine to form a suspension, which was magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.39.+ -. 0.2 °, 9.53.+ -. 0.2 °, 10.00.+ -. 0.2 °, 15.86.+ -. 0.2 °, 16.51.+ -. 0.2 °, 18.29.+ -. 0.2 °, 19.30.+ -. 0.2 °, 21.24.+ -. 0.2 °, as shown in fig. 23. Further characterized by DSC, it has three endothermic peaks at 69 ℃, 100 ℃ and 173 ℃, as shown in FIG. 24.
Example 13
This example provides a crystal of a compound of formula I, prepared as follows:
500mg of the crystals of example 2 were suspended in 1mL of dimethylsulfoxide to form a suspension, magnetically stirred at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 6.27.+ -. 0.2 °, 10.68.+ -. 0.2 °, 12.32.+ -. 0.2 °, 14.99.+ -. 0.2 °, 18.47.+ -. 0.2 °, 20.34.+ -. 0.2 °, 25.44.+ -. 0.2 °, 26.26.+ -. 0.2 °, as shown in FIG. 25. Further characterized by DSC, it has two endothermic peaks at 124℃and 174℃as shown in FIG. 26.
Example 14
This example provides a crystal of a compound of formula I, prepared as follows:
500mg of the crystals of example 2 were suspended in 1mL of pyridine to form a suspension, which was left at 25℃for 3 days, and then the residual liquid was separated by filtration.
XRPD (Bruker D2 PHASER diffractometer,2θ, cu-kα) was used to characterize it as: 7.56.+ -. 0.2 °, 8.78.+ -. 0.2 °, 10.68.+ -. 0.2 °, 12.66.+ -. 0.2 °, 14.46.+ -. 0.2 °, 15.98.+ -. 0.2 °, 17.77.+ -. 0.2 °, 18.52.+ -. 0.2 °, as shown in fig. 27. Further characterized by DSC, it has three endothermic peaks at 74 ℃, 104 ℃ and 173 ℃, as shown in FIG. 28.
Evaluation test:
(1) Stability evaluation
The operation method and the result of the evaluation are shown in the following table:
wherein HPLC was used for purity measurement, and the measurement conditions are shown in the following table:
XRPD characterizations before and after form B stability test are shown in fig. 29; XRPD characterizations before and after the form C stability test are shown in figure 30. As can be seen from the figure: the crystal form B, C can keep good stability under various temperature and humidity conditions, the purity is hardly reduced, and the crystal form structure can be kept unchanged.
(2) Evaluation of hygroscopicity
The operation method of the evaluation specifically comprises the following steps:
hygroscopicity data was collected using an ADVENTURE series dynamic gas phase adsorber (DVS) under N2 protection with a sample dose of 30mg.
The test method is as follows:
1) Relative humidity increase process: 0% RH to 90% RH at a rate of 10% RH/stage;
2) Relative humidity reduction process: 90% RH to 0% RH at a rate of 10% RH/stage.
The results are shown in FIGS. 31-34. FIG. 31 is a DVS plot of form A; FIG. 32 is a representation of XRPD patterns before and after a form A hygroscopicity test; FIG. 33 is a DVS plot of form B; fig. 34 is an XRPD characterization of form B before and after the hygroscopicity test.
FIG. 31 shows that form A has a water absorption of 0.46% at 25℃and 80% relative humidity; FIG. 32 shows that the crystals are stable and the crystal form is unchanged; fig. 33 shows that form B has a water absorption of almost 0 at 25 ℃,80% relative humidity; fig. 34 shows that the crystals were stable and the crystal forms were unchanged.
The applicant states that the present application describes a method for growing an anti-HIV drug intermediate crystal and the resulting crystal and its use by the above examples, but the present application is not limited to the above examples, i.e. it does not mean that the present application must be practiced by relying on the above examples. It should be apparent to those skilled in the art that any modification of the present application, equivalent substitution of raw materials for the product of the present application, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present application and the scope of disclosure.
The preferred embodiments of the present application have been described in detail above, but the present application is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present application within the scope of the technical concept of the present application, and all the simple modifications belong to the protection scope of the present application.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.

Claims (8)

1. A method for growing an anti-HIV drug intermediate crystal, which is characterized by comprising the following steps:
dissolving the raw materials in methanol at 55-65deg.C, filtering, cooling the filtrate to 20-30deg.C at a speed of 0.05-0.15 deg.C/min, stirring for 2-3 hr, and separating to obtain crystals;
the raw materials are crude anti-HIV drug intermediates;
the structure of the anti-HIV drug intermediate is shown as a formula I:
2. the method for growing an anti-HIV drug intermediate crystal according to claim 1, wherein the mass-to-volume ratio of the raw materials to methanol is: each 500mg of the starting material was dissolved in 4-12mL of methanol.
3. The method for growing an anti-HIV drug intermediate crystal according to claim 2, wherein the mass-to-volume ratio of the raw materials to methanol is: each 500mg of the starting material was dissolved in 4-8mL of methanol.
4. The method for growing an anti-HIV drug intermediate crystal according to claim 3, wherein the mass-to-volume ratio of the raw materials to methanol is: each 500mg of the starting material was dissolved in 5.5-6.5mL of methanol.
5. The method for growing an anti-HIV drug intermediate crystal according to claim 4, wherein the cooling rate is 0.09-0.11 ℃/min.
6. The method for growing an anti-HIV drug intermediate crystal according to claim 5, wherein the filtrate is cooled to 24-26 ℃.
7. The method for growing an anti-HIV drug intermediate crystal according to claim 6, wherein the dissolution of the raw materials in methanol is performed at 58-62 ℃.
8. The compound crystal a of formula I produced by the method for producing an anti-HIV drug intermediate crystal according to any one of claims 1 to 7, wherein the compound crystal a of formula I has characteristic diffraction peaks at 8.38±0.2°, 9.44±0.2°, 13.80±0.2°, 16.56±0.2°, 18.82±0.2°, 19.08±0.2°, 19.62±0.2°, and 23.58±0.2° in an X-ray diffraction pattern.
CN202311034040.3A 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same Pending CN117142989A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311034040.3A CN117142989A (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011613178.5A CN114685322B (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal, obtained crystal and application of crystal
CN202311034040.3A CN117142989A (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202011613178.5A Division CN114685322B (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal, obtained crystal and application of crystal

Publications (1)

Publication Number Publication Date
CN117142989A true CN117142989A (en) 2023-12-01

Family

ID=82131748

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311034040.3A Pending CN117142989A (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal A and crystal obtained by same
CN202011613178.5A Active CN114685322B (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal, obtained crystal and application of crystal
CN202311034147.8A Pending CN118026896A (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal and obtained crystal

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011613178.5A Active CN114685322B (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal, obtained crystal and application of crystal
CN202311034147.8A Pending CN118026896A (en) 2020-12-30 2020-12-30 Growth method of anti-HIV drug intermediate crystal and obtained crystal

Country Status (1)

Country Link
CN (3) CN117142989A (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
PL1725566T3 (en) * 2003-12-23 2009-11-30 Janssen Sciences Ireland Uc Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
CN1891698A (en) * 2005-07-06 2007-01-10 刘峰岳 Method forproducing carbamate
RU2009143867A (en) * 2007-04-27 2011-06-10 Тиботек Фармасьютикалз Лтд. (Ie) METHODS FOR PRODUCING N-ISOBUTYL-N- (2-HYDROXY-3-AMINO-4-Phenylbutyl) -PARA-NITROBENZENESULPHANILAMIDE DERIVATIVES
US20120041019A1 (en) * 2008-12-17 2012-02-16 Mutz Mitchell W Protease inhibitors
SI2477992T1 (en) * 2009-09-17 2017-05-31 Mylan Laboratories Limited Processes for the preparation of darunavir and the amorphous form thereof
WO2011061590A1 (en) * 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
CN104387299B (en) * 2014-10-23 2016-08-17 凯莱英医药集团（天津）股份有限公司 The preparation method of 4-amino-N-[(2R, 3S)-3-amino-2-hydroxyl-4-benzene butyl]-N-isobutyl-benzene sulfonamide
CN104478830B (en) * 2014-12-31 2016-06-22 中国医学科学院医药生物技术研究所 One group of tertiary amine comparison peptide derivant and the application in Inhibit HIV-1 Protease thereof
CN108409698B (en) * 2017-02-09 2020-06-26 中国医学科学院医药生物技术研究所 RT/PR double-target HIV inhibitor and preparation method and application thereof

Also Published As

Publication number Publication date
CN114685322B (en) 2023-08-25
CN114685322A (en) 2022-07-01
CN118026896A (en) 2024-05-14

Similar Documents

Publication Publication Date Title
JP5757860B2 (en) Crystalline form of tenofovir disoproxil and process for producing the same
CN102985416B (en) Process of preparing a thrombin specific inhibitor
JP2017061575A (en) Process for the crystallization of reverse transcriptase inhibitor using anti-solvent
CN108794491B (en) Refining method of tofacitinib citrate
KR20080064990A (en) Process for the preparation of cefdinir
KR20150043465A (en) Chemical process
WO2012077138A1 (en) Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
CA2891751A1 (en) Solid and crystalline dutasteride and processes for preparation thereof
CN114685322B (en) Growth method of anti-HIV drug intermediate crystal, obtained crystal and application of crystal
WO2009082913A1 (en) Process for isolation of a mixture of rrrs and sssr configurations of nebivolol intermediates
JP4681545B2 (en) Method for producing crystalline polymorphs of platelet aggregation inhibitors
JP2016175938A (en) Crystallization of epirubicin hydrochloride
CN113072454B (en) Novel crystal form of oxoethylamine compound
KR20060028761A (en) Polymorphs of cabergoline
KR101287425B1 (en) Preparation of crystalline form II of glyceryl phosphoryl choline
JP5952748B2 (en) Novel crystalline form of phthaloyl amlodipine and process for producing high purity amlodipine besylate using the same
CN106432197B (en) Ledipasvir intermediate mono-p-toluenesulfonate, crystal form and preparation method thereof
CN115536710B (en) Preparation method of high-quality cytidine sulfate crystal
CN112552188B (en) Preparation method of sertraline hydrochloride crystal form I
CN111801313B (en) Method for preparing polymorphic form B of treprostinil diethanolamine salt
CN114605416A (en) Preparation method of acatinib crystal form I
CN111072730B (en) Preparation method and application of tulathromycin intermediate salt
US20220315524A1 (en) Preparation method for salicylamine acetate
KR101409573B1 (en) Process for the manufacture of a crystalline pyrazolo［1,5-a］pyrimidine compound
JP4275241B2 (en) Method for producing N-glycyltyrosine and crystal form thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination